These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19010868)

  • 1. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
    Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
    Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R
    J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TroVax in colorectal cancer.
    Rowe J; Cen P
    Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
    Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
    Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
    Harrop R; Shingler WH; McDonald M; Treasure P; Amato RJ; Hawkins RE; Kaufman HL; de Belin J; Kelleher M; Goonewardena M; Naylor S
    Cancer Immunol Immunother; 2011 Jun; 60(6):829-37. PubMed ID: 21387109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
    Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
    Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
    Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4.
    Amato RJ; Xiong Y; Peng H; Mohlere V
    Int J Biol Markers; 2015 Feb; 30(1):e111-21. PubMed ID: 25262701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development.
    Kim DW; Krishnamurthy V; Bines SD; Kaufman HL
    Hum Vaccin; 2010 Oct; 6(10):784-91. PubMed ID: 20975327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
    Amato RJ; Stepankiw M
    Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.